¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"primary effusion lymphoma"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • primary cement
    ÀÏÂ÷½Ã¸àÆ®Áú
  • primary character
    ÀÏÂ÷¼º°Ý
  • primary cholestatic liver disease
    ¿ø¹ß¾µ°³ÁóÁ¤Ã¼°£Áúȯ, ¿ø¹ß´ãÁóÁ¤Ã¼°£Áúȯ
  • primary ciliary dyskinesia
    ¿ø¹ß¼¶¸ð¿îµ¿ÀÌ»óÁõ
  • primary complex
    ¿ø¹ßº¹ÇÕü, Ãʱ⺯ȭ±º
  • primary contact
    ÀÏÂ÷Á¢ÃË
  • primary culture
    ÀÏÂ÷¹è¾ç, óÀ½½É±â
  • primary degenerative dementia
    ¿ø¹ßÅðÇàÄ¡¸Å
  • primary dentin
    ÀÏÂ÷»ó¾ÆÁú
  • primary dentition
    ÀÏÂ÷Ä¡¾Æ
  • primary depression
    ¿ø¹ß¿ì¿ïÁõ
  • primary dysmenorrhea
    ¿ø¹ß¿ù°æÅë
  • primary fissure
    ù°ƴ»õ, ¼Ò³úÁ¦ÀÏ¿­
  • primary focus
    ¿ø¹ßº´ÅÍ
  • primary follicle
    ÀÏÂ÷³­Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • primary ciliary dyskinesia
    ¿ø¹ß¼¶¸ð¿îµ¿ÀÌ»óÁõ
  • primary degenerative dementia
    ÀÏÂ÷ÅðÇàÄ¡¸Å
  • primary pigmented nodular adrenocortical disease
    ÀÏÂ÷»ö¼ÒÄ§Âø°áÁ¤ºÎ½Å°ÑÁúº´
  • primary epilepsy
    ¿ø¹ß°£Áú, ÀÏÂ÷°£Áú
  • primary fissure
    ù°ƴ»õ
  • primary focus
    ¿øº´ÅÍ
  • primary follicle
    ÀÏÂ÷³­Æ÷
  • primary hair
    (¢¡lanugo) ¹è³Á¼ØÅÐ
  • primary host
    (¢¡definitive host) ÃÖÁ¾¼÷ÁÖ
  • primary hypertension
    (¢¡essential hypertension) º»Å°íÇ÷¾Ð
  • primary affect hunger
    ÀÏÂ÷¾ÖÁ¤°¥¸Á
  • primary impression
    ÀÏÂ÷Àλó
  • primary infection
    ÀÏÂ÷°¨¿°
  • primary infiltration
    ÃʱâħÀ±
  • primary insanity
    ÀÏÂ÷Á¤½ÅÀÌ»ó
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • primary amenorrhea
    ¿ø¹ß(¼º) ¹«¿ù°æ(ê«Û¡(àõ) ÙíêÅÌè)
  • primary amine
    ÀÏÂ÷¾Æ¹Î.
  • primary amnion
    ÀÏÂ÷¾ç¸·
  • primary amnion
    ¿ø½Ã¾ç¸·
  • primary amyloidosis
    ¿ø¹ß(¼º) ¾Æ¹Ð·Î À̵åÁõ.
  • primary amyloidosis
    ¿ø¹ß(¼º)(ê«Û¡(àõ)) ¾Æ¹Ð·Î À̵åÁõ
  • primary angle-closure glaucoma
    ¿ø¹ßÆó¼â°¢³ì³»Àå
  • primary antibody response
    ÀÏÂ÷Ç×ü¹ÝÀÀ
  • primary aqueous
    ¿ø¹æ¼ö, ÀÏÂ÷¹æ¼ö
  • primary battery
    ÀÏÂ÷ÀüÁö(ìéó­ï³ò®).
  • primary battery
    ÀÏÂ÷ÀüÁö(ìéó­ï³ò®)
  • primary biliary cirrhosis
    ¿ø¹ß¼º ´ãÁó¼º °£°æº¯(Áõ)
  • primary biliary cirrhosis
    ¿ø¹ß(¼º) ´ãÁó¼º °£°æº¯(Áõ)(ê«Û¡(àõ) ÓÅñðàõ ÊÜÌãܨ(ñø))
  • primary biological productivity
    ÀÏÂ÷»ý¹°»ý»ê·Â(¡­ßæÚªßæß§æ³).
  • primary bone
    ÀÏÂ÷»À
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • histiocytic lymphoma
    Á¶Á÷±¸¸²ÇÁÁ¾
  • immunoblastic lymphoma
    ¸é¿ª ¸ð¼¼Æ÷ ¸²ÇÁÁ¾
  • intestinal lymphoma
    À帲ÇÁÁ¾.
  • large cell anaplastic lymphoma
    ´ë¼¼Æ÷ ÅðÇ༺ ¸²ÇÁÁ¾
  • large cell lymphoma
    ´ë¼¼Æ÷ ¸²ÇÁÁ¾
  • leukemia/lymphoma
    ¹éÇ÷º´/¸²ÇÁÁ¾(ÛÜúìÜ»/¡­ðþ)
  • lymphoepithelioid lymphoma
    ¸²ÇÁÇ¥ÇÇ¾ç ¸²ÇÁÁ¾
  • lymphoma
    ¸²ÇÁÁ¾
  • lymphoma
    ¸²ÇÁÁ¾.
  • lymphoma
    ¸²ÇÁÁ¾(¡­ðþ)
  • lymphoma cells
    ¸²ÇÁÁ¾¼¼Æ÷(¡­á¬øà)
  • lymphoma, Burkitts
    ¹öŶƮ ¸²ÇÁÁ¾
  • lymphoma,burkitts
    ¹öŶ¸²ÇÁÁ¾, Burkitt ¸²ÇÁÁ¾(¡­ðþ)
  • lymphoma,follicular
    ¿©Æ÷¼º¸²ÇÁÁ¾(æ¤øààõ¡­ðþ)
  • lymphoma,large cell, diffuse
    ´ë¼¼Æ÷¼º ¸²ÇÁÁ¾(ÓÞá¬øààõ ¡­ðþ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
ATL Adult T cell Lymphoma
ATLL Adult T cell Leukemia/Lymphoma
CTCL Cutaneous T Cell Lymphoma
NHL Non-Hodgkin's Lymphoma
ABL abetalipoproteinemia; acceptable blood loss; African Burkitt lymphoma; Albright-Butler-Lightwood [sy...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
ATLL Adult T cell lymphoma/leukaemia
ALK Anaplastic Lymphoma Kinase
ALCL Anaplastic large cell lymphoma
BCL B cell lymphoma
B-NHL B cell non Hodgkin's lymphoma
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • primary cephalic vein
    ÀÏÂ÷ ¸Ó¸® Á¤¸Æ
  • primary closure
    ÀÏÂ÷ ºÀÇÕ
  • primary color
    ¿ø»ö, ±âº»»ö
    µ¿ÀǾî=fundamental color. È¥ÇÕ¿¡ ÀÇÇØ¼­ ´Ù¸¥ »ö±òÀ» ¸¸µå´Âµ¥ ÀÌ¿ëµÇ´Â 3°¡Áö ±âº»»öÀ¸·Î ºûÀÇ ºÎ°¡ÀûÀΠȥÇÕÀ̳ª Âø»öÁ¦¸¦ »« °ÍÀÌ´Ù.
  • primary colors subtractive
    °¨»ö
  • primary culture
    Ãʹè¾ç, ÃÊ´ë ¹è¾ç, ÀÏÂ÷ ¹è¾ç
  • primary degenerative dementia
    ¿ø¹ß¼º ÅðÇ༺ Ä¡¸Å
  • primary dentition
    À¯Ä¡¿­, ÀÏÂ÷ »ýÄ¡, Á¦ÀÏ»ýÄ¡
    óÀ½À¸·Î ¸ÍÃâµÇ´Â Ä¡¾Æ·Î º¸Åë ¿µ±¸Ä¡¿¡ ÀÇÇØ¼­ ±³È¯µÈ´Ù.
  • primary diagnosis
    ÀÏÂ÷ Áø´Ü
  • primary displacement
    ÀÏÂ÷¼º ÀüÀ§
  • primary emotional difficulty
    ¿ø¹ß¼º Á¤¼­ Àå¾Ö
  • primary epithelial band
    ÀÏÂ÷ »óÇÇ ¶ì
  • primary failure
    ÀÏÂ÷Àû ¹«È¿
  • primary foci
    ¿ø¹ß º´¼Ò
  • primary follicle
    ÀÏÂ÷ ³­Æ÷, ¿ø½Ã ³­Æ÷, ¿ø½Ã ¿©Æ÷
  • primary gain
    ÀÏÂ÷ À̵æ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
lymphocytic lymphoma <oncology, tumour> A cancer of lymphatic tissues, the tumour cells are mostly abnormal lymphocytes.
(13 Nov 1997)
lymphoma <oncology, tumour> Malignant tumour of lymphoblasts derived from B lymphocytes. most commonly affects children in tropical Africa: both Epstein Barr virus and immunosuppression due to malarial infection are involved.
(18 Nov 1997)
lymphoma, aids-related B-cell lymphoid tumours that occur in association with aids. Patients often present with an advanced stage of disease and highly malignant subtypes including burkitt lymphoma, immunoblastic large-cell lymphoma, small non-cleaved-cell lymphoma and diffuse large-cell lymphoma. The tumours are often disseminated in unusual extranodal sites and chromosomal abnormalities are frequently present. It is likely that polyclonal B-cell lymphoproliferation in aids is a complex result of ebv infection, HIV antigenic stimulation, and T-cell-dependent HIV activation.
(12 Dec 1998)
lymphoma, B-cell A group of heterogeneous lymphoid tumours generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
(12 Dec 1998)
lymphoma, diffuse Malignant lymphoma in which neoplastic cells diffusely infiltrate the entire lymph node without any definite organised pattern. Patients whose lymphomas present a diffuse pattern generally have a more unfavorable survival outlook than those presenting with a follicular or nodular pattern.
(12 Dec 1998)
lymphoma, follicular Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the lymph nodes. The nodules resemble to some extent the germinal centres of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular centre B-lymphocytes. This class of lymphoma usually occurs in older persons, is commonly multinodal, and possibly extranodal. Patients whose lymphomas present a follicular or nodular pattern generally have a more indolent course than those presenting with a diffuse pattern.
(12 Dec 1998)
lymphoma, high-grade One of the three major prognostic groupings for non-hodgkin lymphomas as proposed in the working formulation of the non-hodgkin's lymphoma pathologic classification project sponsored by the national cancer institute (1981). Lymphomas falling within this group have a relatively unfavorable survival potential.
(12 Dec 1998)
lymphoma, intermediate-grade One of the three major prognostic groupings for non-hodgkin lymphomas as proposed in the working formulation of the non-hodgkin's lymphoma pathologic classification project sponsored by the national cancer institute (1981). Lymphomas falling within this group have an intermediate survival potential.
(12 Dec 1998)
lymphoma, large-cell A form of malignant lymphoma in which the malignant cells resemble histiocytes morphologically but are presently considered to be derived from lymphoid elements. These cells are irregular in shape with relatively abundant, frequently acidophilic cytoplasm. Large-cell lymphoma can occur in both nodular (follicular) and diffuse forms, with the latter being more frequently seen.
(12 Dec 1998)
lymphoma, large-cell, diffuse Malignant lymphoma composed of large cells which may be both cleaved and noncleaved. The pattern is predominantly diffuse. most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.
(12 Dec 1998)
lymphoma, large-cell, follicular Malignant lymphoma in which the majority of neoplastic cells within the follicles are large cleaved or noncleaved cells. The degree to which the follicular centre cells retain their ability to form follicles varies with the state of B-cell transformation.
(12 Dec 1998)
lymphoma, large-cell, immunoblastic Malignant lymphoma characterised by the presence of immunoblasts with uniformly round-to-oval nuclei, one or more prominent nucleoli, and abundant cytoplasm. This class may be subdivided into plasmacytoid and clear-cell types based on cytoplasmic characteristics. A third category, pleomorphous, may be analogous to some of the peripheral T-cell lymphomas (lymphoma, T-cell, peripheral) recorded in both the united states and japan.
(12 Dec 1998)
lymphoma, large-cell, ki-1 A large-cell, non-hodgkin's, malignant lymphoma with pleomorphic appearance and reactivity with the monoclonal antibody ki-1. The lymphoma is most often found in the skin and lymph nodes and expresses the ki-1 (CD30) antigen (antigens, CD30) on its surface. It is often mistaken for metastatic carcinoma and malignant histiocytosis.
(12 Dec 1998)
lymphoma, low-grade One of the three major prognostic groupings for non-hodgkin lymphomas as proposed in the working formulation of the non-hodgkin's lymphoma pathologic classification project sponsored by the national cancer institute (1981). Lymphomas falling within this group have a relatively favourable survival potential.
(12 Dec 1998)
lymphoma, lymphoblastic A high-grade malignant lymphoma composed of a diffuse, relatively uniform proliferation of cells with round or convoluted nuclei and scanty cytoplasm. The cells are cytologically similar to the lymphoblasts seen in acute lymphocytic leukaemia, and in some cases, the disease may evolve into a leukaemic phase morphologically indistinguishable from acute t-lymphocytic leukaemia (leukaemia, T-cell, acute). Lymphoblastic lymphoma represents approximately one-third of the cases of non-hodgkin's lymphomas in children and 5% of the cases in adults. It is more prevalent in males.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á